Table 2.

Comparison of Genotypic Drug Resistance Between Study Arms

Mothers	Triple ARV	AZT/sd-NVP
Total enrolled in Burkina and South-Africa	271	264
Sample available <6 weeks after cessation of ARV	152	75 controls
VL >1000 copies/mL	90	48
Could be sequenced	72	41
Total with resistance	1/72	7/41a
NNRTI resistance	K101E	K103N: n = 3; V106L: n = 3; Y188C: n = 1

Abbreviations: ARV, antiretroviral; AZT/sdNVP, zidovudine until delivery with single-dose nevirapine without postpartum prophylaxis; NNRTI, nonnucleoside reverse transcriptase inhibitor; Triple ARV, zidovudine, lamivudine, and lopinavir/ritonavir during pregnancy and breastfeeding; VL, viral load.

^a Zero of 12 women who received an AZT/3TC tail for 1 week after delivery; 7 out of 29 women who received no tail.